A Randomized, Double-blinded, Placebo-controlled, Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin Intravenous Infusion in COVID-19 Pneumonia Patients
Latest Information Update: 03 May 2024
At a glance
- Drugs NuSepin (Primary)
- Indications COVID-19 pneumonia
- Focus Therapeutic Use
- Sponsors Shaperon
Most Recent Events
- 20 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 20 Mar 2023 Planned primary completion date changed from 30 Sep 2022 to 30 Nov 2024.
- 06 May 2022 New trial record